Autoantibodies to MUC1 Glycopeptides Cannot Be Used As a Screening Assay for Early Detection of Breast, Ovarian, Lung or Pancreatic Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 May 9

PMID 23652307

Citations 31

Authors

B Burford

A Gentry-Maharaj

R Graham

D Allen

J W Pedersen

A S Nudelman

O Blixt

E O Fourkala

D Bueti

A Dawnay

J Ford

R Desai

L David

P Trinder

B Acres

T Schwientek

A Gammerman

C A Reis

L Silva

H Osorio

R Hallett

H H Wandall

U Mandel

M A Hollingsworth

I Jacobs

I Fentiman

H Clausen

J Taylor-Papadimitriou

U Menon

J M Burchell

Affiliations

Soon will be listed here.

Abstract

Background: Autoantibodies have been detected in sera before diagnosis of cancer leading to interest in their potential as screening/early detection biomarkers. As we have found autoantibodies to MUC1 glycopeptides to be elevated in early-stage breast cancer patients, in this study we analysed these autoantibodies in large population cohorts of sera taken before cancer diagnosis.

Methods: Serum samples from women who subsequently developed breast cancer, and aged-matched controls, were identified from UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) and Guernsey serum banks to formed discovery and validation sets. These were screened on a microarray platform of 60mer MUC1 glycopeptides and recombinant MUC1 containing 16 tandem repeats. Additional case-control sets comprised of women who subsequently developed ovarian, pancreatic and lung cancer were also screened on the arrays.

Results: In the discovery (273 cases, 273 controls) and the two validation sets (UKCTOCS 426 cases, 426 controls; Guernsey 303 cases and 606 controls), no differences were found in autoantibody reactivity to MUC1 tandem repeat peptide or glycoforms between cases and controls. Furthermore, no differences were observed between ovarian, pancreatic and lung cancer cases and controls.

Conclusion: This robust, validated study shows autoantibodies to MUC1 peptide or glycopeptides cannot be used for breast, ovarian, lung or pancreatic cancer screening. This has significant implications for research on the use of MUC1 in cancer detection.

Citing Articles

Serum antibody screening using glycan arrays.

Marglous S, Brown C, Padler-Karavani V, Cummings R, Gildersleeve J Chem Soc Rev. 2024; 53(5):2603-2642.

PMID: 38305761 PMC: 7616341. DOI: 10.1039/d3cs00693j.

Mucins as Potential Biomarkers for Early Detection of Cancer.

Gautam S, Khan P, Natarajan G, Atri P, Aithal A, Ganti A Cancers (Basel). 2023; 15(6).

PMID: 36980526 PMC: 10046558. DOI: 10.3390/cancers15061640.

Autoantibodies as biomarkers for breast cancer diagnosis and prognosis.

Yang R, Han Y, Yi W, Long Q Front Immunol. 2022; 13:1035402.

PMID: 36451832 PMC: 9701846. DOI: 10.3389/fimmu.2022.1035402.

High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes.

Luo R, Zheng C, Song W, Tan Q, Shi Y, Han X Cancer Sci. 2021; 113(2):770-783.

PMID: 34843149 PMC: 8819333. DOI: 10.1111/cas.15227.

Enhanced humoral immunity in breast cancer patients with high serum concentration of anti-HER2 autoantibody.

Sato Y, Shimoda M, Sota Y, Miyake T, Tanei T, Kagara N Cancer Med. 2021; 10(4):1418-1430.

PMID: 33506656 PMC: 7926031. DOI: 10.1002/cam4.3742.

References

Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A . Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10(4):327-40. DOI: 10.1016/S1470-2045(09)70026-9. View

Blixt O, Bueti D, Burford B, Allen D, Julien S, Hollingsworth M . Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res. 2011; 13(2):R25. PMC: 3219186. DOI: 10.1186/bcr2841. View

Lacombe J, Mange A, Jarlier M, Bascoul-Mollevi C, Rouanet P, Lamy P . Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers. Int J Cancer. 2012; 132(5):1105-13. DOI: 10.1002/ijc.27766. View

Pereira-Faca S, Kuick R, Puravs E, Zhang Q, Krasnoselsky A, Phanstiel D . Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer. Cancer Res. 2007; 67(24):12000-6. DOI: 10.1158/0008-5472.CAN-07-2913. View

Boyle P, Chapman C, Holdenrieder S, Murray A, Robertson C, Wood W . Clinical validation of an autoantibody test for lung cancer. Ann Oncol. 2010; 22(2):383-9. PMC: 3030465. DOI: 10.1093/annonc/mdq361. View

LUBIN R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Cazals D . Serum p53 antibodies as early markers of lung cancer. Nat Med. 1995; 1(7):701-2. DOI: 10.1038/nm0795-701. View

Pedersen J, Blixt O, Bennett E, Tarp M, Dar I, Mandel U . Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer. 2011; 128(8):1860-71. DOI: 10.1002/ijc.25778. View

Pepe M, Feng Z, Janes H, Bossuyt P, Potter J . Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst. 2008; 100(20):1432-8. PMC: 2567415. DOI: 10.1093/jnci/djn326. View

Gotzsche P, Nielsen M . Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2011; (1):CD001877. DOI: 10.1002/14651858.CD001877.pub4. View

10.

Fentiman I, Hanby A, Allen D, Key T, Meilahn E . Hormone dependency of breast tumours developing in the Guernsey Cohort study. Breast Cancer Res Treat. 2005; 97(2):205-8. DOI: 10.1007/s10549-005-9113-8. View

11.

Lu H, Ladd J, Feng Z, Wu M, Goodell V, Pitteri S . Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila). 2012; 5(8):1036-43. PMC: 3790582. DOI: 10.1158/1940-6207.CAPR-11-0558. View

12.

Wandall H, Blixt O, Tarp M, Pedersen J, Bennett E, Mandel U . Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res. 2010; 70(4):1306-13. PMC: 5538776. DOI: 10.1158/0008-5472.CAN-09-2893. View

13.

Chapman C, Healey G, Murray A, Boyle P, Robertson C, Peek L . EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol. 2012; 33(5):1319-26. PMC: 3460172. DOI: 10.1007/s13277-012-0379-2. View

14.

Backstrom M, Link T, Olson F, Karlsson H, Graham R, Picco G . Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells. Biochem J. 2003; 376(Pt 3):677-86. PMC: 1223800. DOI: 10.1042/BJ20031130. View

15.

Tarp M, Sorensen A, Mandel U, Paulsen H, Burchell J, Taylor-Papadimitriou J . Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology. 2006; 17(2):197-209. DOI: 10.1093/glycob/cwl061. View

16.

Kerlikowske K, Grady D, Rubin S, Sandrock C, Ernster V . Efficacy of screening mammography. A meta-analysis. JAMA. 1995; 273(2):149-54. View

17.

Zhong L, Ge K, Zu J, Zhao L, Shen W, Wang J . Autoantibodies as potential biomarkers for breast cancer. Breast Cancer Res. 2008; 10(3):R40. PMC: 2481487. DOI: 10.1186/bcr2091. View

18.

Desmetz C, Mange A, Maudelonde T, Solassol J . Autoantibody signatures: progress and perspectives for early cancer detection. J Cell Mol Med. 2011; 15(10):2013-24. PMC: 4394213. DOI: 10.1111/j.1582-4934.2011.01355.x. View

19.

Zhang J, Tan E . Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn. 2010; 10(3):321-8. PMC: 2896686. DOI: 10.1586/erm.10.12. View

20.

Sorensen A, Reis C, Tarp M, Mandel U, Ramachandran K, Sankaranarayanan V . Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology. 2005; 16(2):96-107. DOI: 10.1093/glycob/cwj044. View